Please wait while the formulary information is being retrieved.
CAMZYOS (mavacamten)
- hypertrophic obstructive cardiomyopathy
10 mg capsule
- 1 capsule (10 mg) by oral route once daily
15 mg capsule
- 1 capsule (15 mg) by oral route once daily
2.5 mg capsule
- 1 capsule (2.5 mg) by oral route once daily
5 mg capsule
- 1 capsule (5 mg) by oral route once daily
Default screening record
- 2 capsules (5 mg) by oral route once daily
- 1 capsule (5 mg) by oral route once daily
- 2 capsules (10 mg) by oral route once daily
- 1 capsule (10 mg) by oral route once daily
- 1 capsule (15 mg) by oral route once daily
- 1 capsule (2.5 mg) by oral route once daily
- None
Contraindicated
- axitinib
- bedaquiline
- Bosulif
- bosutinib
- guanfacine
- Inlyta
- Intuniv Er
- Olysio
- simeprevir
- Sirturo
- Tenex
Severe
Moderate
- None
- None
Contraindicated
- Atrial fibrillation
- Pregnancy
- Severe infection
Severe
Moderate
- None
CAMZYOS (mavacamten)
- hypertrophic obstructive cardiomyopathy
- None
- Dizziness
- Syncope
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Left ventricular failure
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Mavacamten
Safety and efficacy not established in pediatrics.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatrics.
Mavacamten
- Severity Level:
D
- Additional Notes: Insufficient human data available; consider maternal tx benefits
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Mavacamten
Insufficient human data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Mavacamten may cause heart failure. The risk of heart failure is increased if you are also using certain medications. Be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).<br /><br />See also Drug Interactions section. Your doctor should also do heart exams before and during treatment with mavacamten. Your doctor may stop treatment with this medication if heart failure occurs.<br /><br />Get medical help right away if you have any symptoms of heart failure (such as shortness of breath, swelling ankles/feet, unusual tiredness, unusual/sudden weight gain). For patients to receive this medication, all doctors, pharmacists, and patients must agree to, understand, and carefully follow the requirements of the Camzyos REMS Program. These requirements apply in the United States. If you live in Canada or any other country, consult your doctor and pharmacist for your country's regulations.
| Hypertrophic obstructive cardiomyopathy | |
| I42.1 | Obstructive hypertrophic cardiomyopathy |
| 0-9 | A-Z |
|---|---|
| I42.1 | Obstructive hypertrophic cardiomyopathy |
Formulary Reference Tool